Corticosteroids: Triamcinolone, dexamethasone and fluocinolone

Developments in Ophthalmology

Volumn 55, Issue , 2015, Pages 221-231

  Cáceres Del Carpio, Javier ^a   Costa, Rodrigo Donato ^a,b   Haider, Asghar ^a   Narayanan, Raja ^c   Kuppermann, Baruch D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Instituto Donato Oftalmologia   (Brazil)

^c L V PRASAD EYE INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLUOCINOLONE; FLUOCINOLONE ACETONIDE; GLUCOCORTICOID; TRIAMCINOLONE;

ANALOGS AND DERIVATIVES; DRUG DELIVERY SYSTEM; HUMAN; MACULAR EDEMA;

DEXAMETHASONE; DRUG DELIVERY SYSTEMS; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; TRIAMCINOLONE;

EID: 84947245889     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000431198     Document Type: Article

References (76)

1. Weijtens O, Schoemaker RC, Romijn FP, et al. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology 2002; 109:1887-1891.
2. Weijtens O, Feron EJ, Schoemaker RC, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol 1999; 128:192-197.
3. Weijtens O, van der Sluijs FA, Schoemaker RC, et al. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol 1997; 123:358-363.
4. Graham RO, Peyman GA: Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol 1974; 92:149-154.
5. Peyman GA, Rose M, Sanders D: Intravitreal antibiotic injection and vitrectomy in acute bacterial endophthalmitis. Can J Ophthalmol 1976; 11:188-190.
6. Machemer R, Sugita G, Tano Y: Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979; 77:171-180.
7. Tano Y, Sugita G, Abrams G, Machemer R: Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 1980; 89:131-136.
8. Herrero-Vanrell R, Cardillo JA, Kuppermann BD: Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol 2011; 5:139-146.
9. Kuppermann BD, Zacharias LC, Kenney MC: Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2014; 112:116-141.
10. Zacharias LC, Lin T, Migon R, et al. Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. Retina 2013; 33:522-531.
11. Ferris FL 3rd, Patz A: Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984; 28(suppl):452-461.
12. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341:309-315.
13. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005; 46:1440-1444.
14. Felinski EA, Antonetti DA: Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res 2005; 30:949-957.
15. Antonetti DA, Wolpert EB, DeMaio L, et al. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 2002; 80:667-677.
16. Schindler RH, Chandler D, Thresher R, Machemer R: The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982; 93:415-417.
17. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003; 110:681-686.
18. Hosseini K, Matsushima D, Johnson J, et al. Pharmacokinetic study of dexamethasone disodium phosphate using intravitreal, subconjunctival, and intravenous delivery routes in rabbits. J Ocul Pharmacol Ther 2008; 24:301-308.
19. Nabih M, Peyman GA, Tawakol ME, Naguib K: Toxicity of high-dose intravitreal dexamethasone. Int Ophthalmol 1991; 15:233-235.
20. Kwak HW, D'Amico DJ: Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992; 110:259-266.
21. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125:309-317.
22. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011; 52:80-86.
23. Sanford M: Fluocinolone acetonide intravitreal implant (Iluvien® ). Drugs 2013; 73:187-193.
24. Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology 2013; 120:583-587.
25. Jonas JB, Hayler JK, Söfker A, et al. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131:468-471.
26. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109:920-927.
27. Ciardella AP, Klancnik J, Schiff W, et al. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 2004; 88:1131-1136.
28. Jonas JB, Degenring RF, Kamppeter BA, et al. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004; 138:158-160.
29. Audren F, Tod M, Massin P, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004; 45:3435-3441.
30. Jonas JB, Kamppeter BA, Harder B, et al. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006; 22:200-207.
31. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127:245-251.
32. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118:609-614.
33. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117:1064-1077.e35.
34. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015; 122:375-381.
35. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128:289-296.
36. Pacella E, Vestri AR, Muscella R, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex® ) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013; 7:1423-1428.
37. Lazic R, Lukic M, Boras I, et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina 2014; 34:719-724.
38. Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31:915-923.
39. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121:1904-1914.
40. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118:1580-1587.
41. Park CH, Jaffe GJ, Fekrat S: Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003; 136:419-425.
42. Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004; 122:1131-1136.
43. Bashshur ZF, Ma'luf RN, Allam S, et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 2004; 122:1137-1140.
44. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127:1101-1114.
45. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117:1134-1146.e3.
46. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 2011; 118:2453-2460.
47. Mayer WJ, Wolf A, Kernt M, et al. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye (Lond) 2013; 27:816-822.
48. Ozkok A, Saleh OA, Sigford DK, et al. The OMAR Study: comparison of Ozurdex and triamcinolone acetonide for refractory cystoid macular edema in retinal vein occlusion. Retina 2015, Epub ahead of print.
49. Danis RP, Ciulla TA, Pratt LM, Anliker W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20:244-250.
50. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003; 87:462-468.
51. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003; 121:667-673.
52. Jonas JB, Kreissig I, Degenring RF: Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration. Br J Ophthalmol 2004; 88:1557-1562.
53. Jonas JB, Akkoyun I, Budde WM, et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004; 122:218-222.
54. Spaide RF, Sorenson J, Maranan L: Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112:301-304.
55. Augustin AJ, Schmidt-Erfurth U: Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 141:638-645.
56. Augustin AJ, Puls S, Offermann I: Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27:133-140.
57. Ahmadieh H, Taei R, Riazi-Esfahani M, et al. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial. Retina 2011; 31:1819-1826.
58. Barnes PJ: Glucocorticosteroids: current and future directions. Br J Pharmacol 2011; 163:29-43.
59. Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129:545-553.
60. Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008; 126:1191-1201.
61. Jonas JB, Kreissig I, Degenring R: Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87:24-27.
62. Bakri SJ, Beer PM: The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003; 34:386-390.
63. Moshfeghi AA, Scott IU, Flynn HW Jr, Puliafito CA: Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004; 138:489-492.
64. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003; 23:686-691.
65. Yeung CK, Chan KP, Chan CK, et al. Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol 2004; 48:236-242.
66. Narayanan R, Mungcal JK, Kenney MC, et al. Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci 2006; 47:722-728.
67. Tokuda K, Tsukamoto T, Fujisawa S, Matsubara M: Evaluation of toxicity due to vital stains in isolated rat retinas. Acta Ophthalmol Scand 2004; 82:189-194.
68. Kivilcim M, Peyman GA, El-Dessouky ES, et al. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 2000; 31:474-478.
69. Gaston H, Absolon MJ, Thurtle OA, Sattar MA: Steroid responsiveness in connective tissue diseases. Br J Ophthalmol 1983; 67:487-490.
70. Podos SM, Becker B, Morton WR: High myopia and primary open-Angle glaucoma. Am J Ophthalmol 1966; 62:1038-1043.
71. Smithen LM, Ober MD, Maranan L, Spaide RF: Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004; 138:740-743.
72. Mueller AJ, Jian G, Banker AS, et al. The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure. Am J Ophthalmol 1998; 125:158-163.
73. Gillies MC, Kuzniarz M, Craig J, et al. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005; 112:139-143.
74. Thompson JT: Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 2006; 141:629-637.
75. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136:791-796.
76. Patel SR, Berezovsky DE, McCarey BE, et al. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci 2012; 53:4433-4441.